Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum-Reference-Cited by-同舟云学术

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum

Published:2021-10-14 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Tosun Duygu¹²^ORCID,Demir Zeynep²,Veitch Dallas P.¹²,Weintraub Daniel³,Aisen Paul⁴,Jack Clifford R.⁵,Jagust William J.⁶,Petersen Ronald C.⁷⁸,Saykin Andrew J.⁹¹⁰¹¹,Shaw Leslie M.¹²,Trojanowski John Q.¹²,Weiner Michael W.¹²,

Affiliation:

1. San Francisco Veterans Affairs Medical Center San Francisco California USA

2. Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco California USA

3. Department of Psychiatry University of Pennsylvania Philadelphia Pennsylvania USA

4. Alzheimer's Therapeutic Research Institute (ATRI) Keck School of Medicine University of Southern California San Diego California USA

5. Department of Radiology Mayo Clinic Rochester Minnesota USA

6. School of Public Health and Helen Wills Neuroscience Institute University of California, Berkeley Berkeley California USA

7. Division of Epidemiology Department of Health Sciences Research Mayo Clinic Rochester Minnesota USA

8. Department of Neurology Mayo Clinic Rochester Minnesota USA

9. Center for Neuroimaging Department of Radiology and Imaging Sciences Indiana University School of Medicine Indianapolis Indiana USA

10. Indiana Alzheimer Disease Center Indiana University School of Medicine Indianapolis Indiana USA

11. Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA

12. Department of Pathology and Laboratory Medicine Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12480

Reference56 articles.

1. Clinical development of aducanumab, an anti‐aβ human monoclonal antibody being investigated for the treatment of early Alzheimer's disease;Budd Haeberlein S;J Prev Alzheimers Dis,2017

2. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

3. To what degree is late life cognitive decline driven by age-related neuropathologies?

4. Person-specific contribution of neuropathologies to cognitive loss in old age

5. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial;eBioMedicine;2024-01

2. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults;Neurology;2023-12-12

3. Causal inference in drug discovery and development;Drug Discovery Today;2023-10

4. Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD;Annals of Neurology;2023-09-30

5. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022;Alzheimer's & Dementia;2023-09-12